Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06504147 · ClinicalTrials.gov registry record · Phase 2
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
A Phase 2 study of Ovarian Cancer and Peritoneal Carcinomatosis, sponsored by Oncoinvent Solutions AS.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 114
- Enrollment target
- 10
- Study locations
NCT06504147: Recruiting Phase 2 study of Ovarian Cancer and Peritoneal Carcinomatosis, sponsored by Oncoinvent Solutions AS.
NCT06504147 is a Phase 2 study of Ovarian Cancer and Peritoneal Carcinomatosis that is actively recruiting participants, run by Oncoinvent Solutions AS. The registered enrollment target is 114 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (84% lower). The trial reports 10 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06504147, a Phase 2 study of Ovarian Cancer and Peritoneal Carcinomatosis, is actively recruiting participants, sponsored by Oncoinvent Solutions AS.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 114 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Phase 2, controlled, randomised, parallel assignment, open label, multicentre study to evaluate efficacy and safety of a single intraperitoneal injection of Radspherin® in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer, with peritoneal metastasis that are HR proficient and scheduled to undergo NACT and IDS. The study will be conducted in 2 parts; first, a Safety Lead-in Cohort will be recruited followed by the randomised part of the study. For both parts of the study, patients must be scheduled to undergo NACT and IDS and complete resection to no residual tumour (R0) should be deemed to be achievable during diagnostic work-up. Patients in both parts of the study will undergo the same procedures and assessments.
Primary Outcome
To compare PFS in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian, fallopian tube, or primary peritoneal cancer1 with peritoneal metastasis that are HR proficient following Radspherin® treatment versus no treatment.
Conditions Studied
Interventions
- DRUG Radspherin
Study Locations (10)
Other
- UZ Leuven - Leuven
- Fondazione Policlinico Universitario A. Gemelli IRCCS - Roma
- The Norwegian Radiumhospital - Oslo
- Hospital Universitari de Bellvitge - Barcelona
- Clinica Universidad de Navarra - Madrid
- Clinica Universidad de Navarra - Pamplona
- Hospital Universitari i Politècnic La Fe - Valencia
- Imperial College Healthcare NHS Trust - London
- University Hospital Southampton NHS Foundation Trust - Southampton
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2024-06-15 |
| Est. Completion | 2031-02-28 |
| Phase | Phase 2 |
What NCT06504147 shows while recruiting
NCT06504147 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Radspherin is the first listed.
NCT06504147 lists 10 locations in 2 states (Other, Florida).
Frequently Asked Questions
What is clinical trial NCT06504147 about?
NCT06504147 is a clinical study titled "A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery". This is a Phase 2, controlled, randomised, parallel assignment, open label, multicentre study to evaluate efficacy and safety of a single intraperitoneal injection of Radspherin® in patients with primary advanced high-grade serous or high-grade endometrioid epithelial ovarian cancer, fallopian tube,...
What is the current status of trial NCT06504147?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2024-06-15. Estimated completion is 2031-02-28.
What conditions does trial NCT06504147 study?
This clinical trial studies the following conditions: Ovarian Cancer, Peritoneal Carcinomatosis.
What interventions are being tested in trial NCT06504147?
The interventions under investigation include: Radspherin (DRUG).
Who is sponsoring clinical trial NCT06504147?
This trial is sponsored by Oncoinvent Solutions AS, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06504147 being conducted?
This trial has 10 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06504147's enrollment target sits among peer trials
114 138th of 322 higher than 185 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
-
A Study of Isoquercetin in People With Ovarian Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI